Patents by Inventor Amgen, Inc.
Amgen, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140134157Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.Type: ApplicationFiled: March 14, 2013Publication date: May 15, 2014Applicants: AMGEN FREMONT INC., AMGEN INC.Inventors: Amgen Inc., Amgen Fremont Inc.
-
Publication number: 20140030270Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.Type: ApplicationFiled: May 2, 2013Publication date: January 30, 2014Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20140017166Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.Type: ApplicationFiled: April 25, 2013Publication date: January 16, 2014Applicants: AMGEN, INC., U3 PHARMA GMBHInventors: U3 PHARMA GMBH, AMGEN, INC.
-
Publication number: 20140004107Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: May 17, 2013Publication date: January 2, 2014Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130225552Abstract: Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.Type: ApplicationFiled: February 28, 2013Publication date: August 29, 2013Applicant: AMGEN INC.Inventor: Amgen Inc.
-
Publication number: 20130217625Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.Type: ApplicationFiled: April 11, 2013Publication date: August 22, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130209466Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.Type: ApplicationFiled: April 11, 2013Publication date: August 15, 2013Applicant: AMGEN INC.Inventor: AMGEN INC.
-
Publication number: 20130203968Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicants: UCB PHARMA S.A., AMGEN INC.Inventors: Amgen Inc., UCB Pharma S.A.
-
Publication number: 20130197191Abstract: Binding proteins that specifically bind to ?-Klotho or portions thereof, FGFR1c or portions thereof, or both FGFR1c and ?-Klotho, and optionally other proteins as well are provided. Coding sequences, methods of treatment and pharmaceutical compositions are also provided.Type: ApplicationFiled: January 10, 2013Publication date: August 1, 2013Applicant: AMGEN INC.Inventor: AMGEN INC.
-
Publication number: 20130195795Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.Type: ApplicationFiled: November 8, 2012Publication date: August 1, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130189281Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.Type: ApplicationFiled: September 27, 2012Publication date: July 25, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130171695Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.Type: ApplicationFiled: March 11, 2013Publication date: July 4, 2013Applicant: AMGEN INC.Inventor: Amgen Inc.
-
Publication number: 20130171168Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: March 11, 2013Publication date: July 4, 2013Applicants: MEDAREX, INC., AMGEN INC.Inventors: Amgen Inc., Medarex, Inc.
-
Publication number: 20130165445Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-5 and 7-8, D?, L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: ApplicationFiled: February 1, 2013Publication date: June 27, 2013Applicant: AMGEN INC.Inventor: AMGEN INC.
-
Publication number: 20130164292Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: December 28, 2012Publication date: June 27, 2013Applicants: MEDAREX, INC., AMGEN, INC.Inventors: Amgen, Inc., Medarex, Inc.
-
Publication number: 20130150339Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.Type: ApplicationFiled: December 6, 2012Publication date: June 13, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130143796Abstract: The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: November 19, 2012Publication date: June 6, 2013Applicant: AMGEN INC.Inventor: AMGEN INC.
-
Publication number: 20130144041Abstract: The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.Type: ApplicationFiled: November 15, 2012Publication date: June 6, 2013Applicant: AMGEN INC.Inventor: AMGEN INC.
-
Publication number: 20130142799Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: November 19, 2012Publication date: June 6, 2013Applicant: AMGEN, INC.Inventor: Amgen, Inc.
-
Publication number: 20130121990Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.Type: ApplicationFiled: January 16, 2013Publication date: May 16, 2013Applicant: AMGEN INC.Inventor: Amgen Inc.